[{"indications": "Indications\u00a0see notes above", "name": "COLISTIMETHATE SODIUM", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.7 Some other antibacterials", "Polymyxins", "COLISTIMETHATE SODIUM"], "cautions": "Cautions\u00a0acute porphyria (section 9.8.2); risk of bronchospasm on inhalation\u2014may\r\nbe prevented or treated with a selective beta2 agonist; interactions: Appendix 1 (polymyxins)", "side-effects": "Side-effects\u00a0Specific side-effects for parenteral treatment\u00a0Neurotoxicity reported especially with excessive doses (including\r\napnoea, perioral and peripheral paraesthesia, vertigo, headache, muscle\r\nweakness; rarely vasomotor instability, slurred speech, confusion,\r\npsychosis, visual disturbances), nephrotoxicity, rashSpecific side-effects for inhaled treatment\u00a0Sore\r\nthroat, sore mouth, cough, bronchospasm", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/127956.htm", "doses": ["By slow intravenous injection into a totally\r\nimplantable venous access device, or by intravenous\r\ninfusion (but see notes above), adult and child body-weight under 60\u00a0kg,\r\n50\u00a0000\u201375\u00a0000\u00a0units/kg daily in 3 divided doses; body-weight over\r\n60\u00a0kg, 1\u20132\u00a0million units every 8 hours", " Plasma concentration monitoring required\r\nin renal impairment; recommended \u2018peak\u2019 plasma-colistimethate sodium\r\nconcentration (approx. 30 minutes after intravenous injection or infusion)\r\n10\u201315\u00a0mg/litre (125\u2013200\u00a0units/mL)", "By inhalation of nebulised solution, adult and child over\r\n2 years, 1\u20132\u00a0million\u00a0units twice daily; increased to 2 million\u00a0units\r\n3 times daily for subsequent respiratory isolates of Ps.\r\naeruginosa; child 1 month\u20132\r\nyears, 0.5\u20131\u00a0million\u00a0units twice daily; increased to 1 million\u00a0units\r\n3 times daily for subsequent respiratory isolates of Ps.\r\naeruginosa"], "pregnancy": "Pregnancy\u00a0avoid\u2014possible risk of fetal toxicity especially\r\nin second and third trimesters"}]